A5015727433- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Frailty in Older Adults
- Multiple and Secondary Primary Cancers
Oslo University Hospital
2019-2023
University of Oslo
2019-2023
Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest substantial heterogeneity phenotypes and suppressive capacities Tregs, emphasizing importance understanding Treg diversity need for additional markers identify highly Tregs. Here, we applied single-cell RNA sequencing T-cell...
Abstract Patients with diffuse large B-cell lymphoma (DLBCL) have a median age of 70 years. Yet, empirical knowledge about the treatment older patients is limited because they are frequently excluded from clinical trials. We aimed to construct simplified frailty score and examine survival treatment-related mortality (TRM) according status intensity in an real-world population DLBCL. All aged ≥70 years diagnosed DLBCL between 2006 2016 southeastern Norway (N = 784) were included...
The International prognostic Index (IPI) is the most widely used clinical prediction model for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but may be suboptimal in older patients. We aimed to develop externally validate a older, RCHOP- DLBCL by examining geriatric assessment lymphoma-related parameters real-world cohorts. A population-based training set of 365 R-CHOP-treated ≥70 years was...
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) comprise ∼8% of tumors diffuse large (DLBCL) morphology [1] is associated poor outcome after standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy [2]. Accurate diagnosis resource intensive as it requires fluorescence in situ hybridization (FISH) all DLBCL tumors. Improved facilitated diagnostics the double-hit population needed to select these patients for new treatment...